Loading
Molecular pumps on cancer cells that eject chemotherapy and ADC payloads before they can act.
Drug efflux pumps are ABC transporters on cancer cells that eject chemotherapy and ADC payloads before they can act. The main ones are ABCB1 (P-glycoprotein or MDR1), ABCG2 (BCRP) and ABCC1 (MRP1), with substrates including taxanes, anthracyclines, MMAE, DXd and, for ABCG2, SN-38. They are upregulated in mesenchymal and stem-like states, hence the term's place in the Epithelial-mesenchymal transition & drug efflux pathway; some newer payloads and radiation are efflux-independent, whereas pump inhibitors failed clinically because of toxicity. It is linked to the Antibody-drug conjugate (ADC) and Cytotoxic chemotherapy technologies, to the bottleneck Acquired resistance to every therapy, and to ideas on payload-class switching and efflux-agnostic therapy for mesenchymal TNBC.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares T030 (belotecan derivative), SN-38, DXd, MMAE.
Shares DXd, MMAE, Tubulin inhibitor payloads, Topoisomerase-I inhibitor payloads.
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, Payload-class switching as the rule for ADC sequencing, Topoisomerase-I inhibitor payloads, Drug efflux pumps (ABC transporters).
Shares Drug efflux pumps (ABC transporters), The blood-brain barrier & brain metastasis, Epithelial-mesenchymal transition & drug efflux.
Shares SN-38, DXd, Topoisomerase-I inhibitor payloads, Antibody-drug conjugate (ADC).
Shares Topoisomerase-I inhibitor payloads, Drug efflux pumps (ABC transporters), Antibody-drug conjugate (ADC).
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
Shares MMAE, Tubulin inhibitor payloads, Antibody-drug conjugate (ADC).